Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026)

Zymeworks' (ZYME) quarterly Total Non-Current Liabilities came in at $314.3 million in Q1 2026, up 215.3% year-on-year from $99.7 million in Q1 2025, and up 304.32% quarter-over-quarter from $77.7 million in Q4 2025.

Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Zymeworks has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $314.3 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $314.3 million, up 215.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $314.3 million (up 215.3% YoY), and the FY2025 annual result was $77.7 million, down 37.0% from the prior year.
  • Total Non-Current Liabilities came in at $314.3 million for Q1 2026 at Zymeworks, up from $77.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $314.3 million in Q1 2026 to a low of $73.1 million in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $117.6 million (2022), against an average of $126.8 million.
  • Across the five-year window, Total Non-Current Liabilities tumbled 37.0% in 2025 and surged 215.3% in 2026, its largest moves.
  • Zymeworks' Total Non-Current Liabilities stood at $154.1 million in 2022, then decreased by 25.79% to $114.4 million in 2023, then rose by 7.89% to $123.4 million in 2024, then sank by 37.0% to $77.7 million in 2025, then surged by 304.32% to $314.3 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $314.3 million (Q1 2026), $77.7 million (Q4 2025), and $76.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Zymeworks 1.73 Bn 1.36 Bn - 314.35 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 314.35 Mn
Dec 31, 2025 77.75 Mn
Sep 30, 2025 76.93 Mn
Jun 30, 2025 73.05 Mn
Mar 31, 2025 99.70 Mn
Dec 31, 2024 123.40 Mn
Sep 30, 2024 119.25 Mn
Jun 30, 2024 108.24 Mn
Mar 31, 2024 114.16 Mn
Dec 31, 2023 114.37 Mn
Sep 30, 2023 131.73 Mn
Jun 30, 2023 152.08 Mn
Mar 31, 2023 125.70 Mn
Dec 31, 2022 154.13 Mn
Sep 30, 2022 117.57 Mn
Dec 31, 2021 137.29 Mn